Thymosinβ4: a novel assessed biomarker of the prognosis of acute-on-chronic liver failure patient?

Liu Y, Han T, Zhu ZY, Li Y

Clinics and research in hepatology and gastroenterology24 Mar 2014Cited by 8 (Europe PMC)

PMID24674841DOI10.1016/j.clinre.2014.02.004PepBankPUB-24674841

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic liver failure, serum Tβ4 levels were lower than in healthy controls.
In plain wordsPeople with acute-on-chronic liver failure had lower levels of the body's own Tβ4 in blood than healthy people.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSerum Tβ4 in AoCLF patients versus healthy controls
Study
n: not reported in source
Comparator
Healthy controls
Outcome group
Endogenous peptide levels · Liver
Measurements
Median serum Tβ4, AoCLF
0.412 μg/mL
AoCLF patients
Median serum Tβ4, controls
9.271 μg/mL
healthy controls
Source sentences
Summary
Serum Tβ4 levels of AoCLF patients [0.4120 (0.2447-0.7492)μg/mL] were lower than healthy controls [9.2710 (5.1660-13.2485)μg/mL] (P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Serum Tβ4 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the CTP and MELD scores were calculated for each patient.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2467484101
02HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic liver failure, serum Tβ4 concentrations were lower in those who died than in survivors.
In plain wordsAmong people with acute-on-chronic liver failure, those who died had lower levels of the body's own Tβ4 than survivors.
Peptide
Thymosin beta-4 (human)
Outcome
DecreaseSerum Tβ4 in AoCLF patients who died versus survivors
Study
n: not reported in source
Comparator
Survivors
Outcome group
Endogenous peptide levels · Liver
Source sentences
Summary
Compared to survivors, lower Tβ4 concentrations, higher CTP and MELD scores (P<0.001, respectively) were observed in AoCLF patients who died.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum Tβ4 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the CTP and MELD scores were calculated for each patient.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2467484102
03HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic liver failure, serum Tβ4 levels correlated negatively with CTP scores and with MELD scores.
In plain wordsIn people with acute-on-chronic liver failure, lower levels of the body's own Tβ4 were linked to higher severity scores.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableCorrelation of Tβ4 with CTP and MELD scores
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Liver
Source sentences
Summary
There were negative correlations between Tβ4 levels and CTP scores (P<0.001), MELD scores (P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Serum Tβ4 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the CTP and MELD scores were calculated for each patient.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2467484103
04HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic liver failure, a serum Tβ4 concentration of 0.3840 μg/mL was identified as a cut-off value for stratification.
In plain wordsIn people with acute-on-chronic liver failure, a blood Tβ4 level of 0.3840 μg/mL was found as a cut-off for sorting patients by outlook.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 cut-off value for patient stratification
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Liver
Measurements
Cut-off Tβ4
0.384 μg/mL
AoCLF patients
Source sentences
Summary
A CTP score of 11.5, a MELD score of 21.63 and a Tβ4 concentration of 0.3840μg/mL were identified as the cut-off values for the stratification of AoCLF patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum Tβ4 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the CTP and MELD scores were calculated for each patient.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2467484104
05HumanEndogenous levelObservational studyOther
In patients with acute-on-chronic liver failure, MELD of 21.63 or higher combined with Tβ4 below 0.3840 μg/mL discriminated more exactly between patients who would survive and die.
In plain wordsIn people with acute-on-chronic liver failure, a high MELD score together with low levels of the body's own Tβ4 separated survivors from non-survivors more exactly.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableDiscrimination of survival by MELD plus Tβ4
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Liver
Source sentences
Summary
MELD≥21.63 combined with Tβ4<0.3840μg/mL can more exactly discriminate between the patients who would survive and die.
1 context sentence(design, population, supporting numbers)
Summary · context
Serum Tβ4 levels were measured by enzyme-linked immunosorbent assay (ELISA), and the CTP and MELD scores were calculated for each patient.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2467484105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.